Insights on treating an over-the-counter-type subgroup: Data from the Air Force/Texas Coronary Atherosclerosis Prevention Study population

American Journal of Cardiology

Volumn 85, Issue 12 SUPPL. 1, 2000, Pages 8-14

  Gotto Jr , Antonio M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NON PRESCRIPTION DRUG; PLACEBO;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR;

EID: 0343729911     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)00945-0     Document Type: Article

References (13)

1. Kannel W.B. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 76:(suppl 9):1995;69C-77C.
2. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels Cholesterol and Recurrent Events Trial investigators . N Engl J Med. 335:1996;1001-1009.
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group . N Engl J Med. 339:1998;1349-1357.
4. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of AFCAPS/TexCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study) . JAMA. 279:1998;1615-1622.
5. Hoerger T.J., Bala M.V., Bray J.W., Wilcosky T.C., LaRosa J. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol. 82:1998;61-65.
6. Downs J.R., Beere P.A., Whitney E., Clearfield M., Weis S., Rochen J., Stein E.A., Shapiro D.R., Langendorfer A., Gotto A.M. Jr. Design and rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol. 80:1997;287-293.
7. U.S. Department of Health and Human Services (DHHS). National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-94, NHANES III Examination Data File (CD ROM). Public Use Data File Documentation Number 76200. Hyattsville, MD: Centers for Disease Control and Prevention, 1996.
8. The Lipid Research Clinics Coronary Primary Prevention Trial results, I Reduction in incidence of coronary heart disease . JAMA. 251:1984;351-364.
9. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., Manninen V., et al. Helsinki Heart Study Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease . N Engl J Med. 317:1987;1237-1245.
10. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia West of Scotland Coronary Prevention Study Group . N Engl J Med. 333:1995;1301-1307.
11. Johnson C.L., Rifkind B.M., Sempos C.T., Carroll M.D., Bachorik P.S., Briefel R.R., Gordon D.J., Burt V.L., Brown C.D., Lippel K., et al. Declining serum total cholesterol levels among US adults the National Health and Nutrition Examination Surveys . JAMA. 269:1993;3002-3008.
12. Neaton J.D., Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease overall findings and differences by age for 316,099 white men (A Multiple Risk Factor Intervention Trial Research Group) . Arch Intern Med. 152:1992;56-64.
13. Gotto A.M. Jr. Lipid-lowering therapy for the primary prevention of coronary heart disease. J Am Coll Cardiol. 33:1999;2078-2082.